Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC

Executive Summary

The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.

You may also be interested in...

Exelixis' Cotellic Fails To IMblaze A Trail In Colorectal Cancer

The failure of a Cotellic/Tecentriq combo in the IMblaze370 trial highlights Exelixis' dependence on its renal cell carcinoma drug CaboMetyx and the treatment challenges of the aggressive and difficult-to-treat disease that is metastatic colorectal cancer.

Ipsen CFO: 'We Need To Stay Focused' So Didn't Bid For Onivyde ex-US Rights

Ipsen let French peer Servier buy Shire's oncology assets, including rights for Onivyde in Europe, to concentrate on its coming Cabometyx EU launch and ongoing launch of Onivyde in the US.

Ipsen Dreams Of Capital Position In Oncology

Ipsen's chief medical officer Sotirios Stergiopoulos talks about the company's R&D and licensing strategy that he hopes will push Ipsen's oncology unit to the next level.  

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts